SYRE: Advancing innovative antibody combinations for autoimmune diseases with pivotal data expected in 2027
The company is advancing best-in-class antibody therapies for autoimmune diseases, with a focus on IBD and expansion into rheumatic and dermatologic indications. Strong recent data, a robust financial position, and a differentiated co-formulation strategy support multiple upcoming readouts and pote…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.